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Brief Clinical ReportsProlonged use of right ventricular assist device for refractory graft
failure following orthotopic heart transplantationPietro Bajona, MD,* Stefano Salizzoni, MD,* Stacey H. Brann, MD, Judy Coyne, CRNP,
Christian Bermudez, MD, Robert Kormos, MD, and Yoshiya Toyoda, MD, PhD, Pittsburgh, PaThe use of mechanical circulatory support for posttransplant
right ventricular (RV) failure is well described.1 Nakatani
and colleagues2 first reported on the feasibility of the right
heart assist for acute RV failure after heart transplantation.
However, longest possible duration of the RV support is
unknown for recovery following heart transplantation.3
We report a case of successful use of a Thoratec (Thoratec
Corporation, Pleasanton, Calif) ventricular assist device
(IVAD) as a bridge to recovery for prolonged RV failure
following heart transplantation.CLINICAL SUMMARY
The patient was a 55-year-old (weight, 79 kg; height, 168
cm) African-American man, diagnosed with idiopathic noni-
schemic dilated cardiomyopathy. During the 4 months prior
to cardiac transplantation, he was repeatedly hospitalized for
decompensated congestive heart failure despite optimal medi-
cal therapy. He eventually required intravenous dobutamine
and intra-aortic balloon pump prior to his heart transplantation.
His past medical history included hypertension, dyslipidemia,
mild chronic renal insufficiency (creatinine 1.4 mg/dL), and
smoking (40 pack/y). Preoperative transthoracic echocardiog-
raphy (TTE) revealed a severely dilated, diffusely hypokinetic
left ventricle with severe systolic dysfunction (ejection fraction
[EF] 10%–15%). Cardiac catheterization on dobutamine
revealed a mean right atrial pressure of 4.5 mm Hg; mean
pulmonary artery pressure, 24 mm Hg; transpulmonary gradi-
ent, 12.5mmHg; pulmonary vascular resistance, 2.79 d $ cm $
s5; and cardiac index 2.4 L $ min1 $ m2.
He was deemed eligible for transplantation by our multi-
disciplinary team and subsequently underwent orthotopic
cardiac transplantation. The donor was a 28-year-old
(weight, 89 kg; height, 168 cm) woman with a mild tricuspid
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The Journal of Thoracic and Caischemic time was 264 minutes. Cardiopulmonary bypass
was weaned with multiple inotropes, nitric oxide, and intra-
aortic balloon pump support due to severe RV failure. Even-
tually, a Bio-Medicus (Medtronic, Minneapolis, Minn) RV
assist device (RVAD; right atrium to pulmonary artery) sup-
port of 4 to 5 L/min was instituted, with immediate hemody-
namic improvement, and after 72 hours RVAD was weaned
successfully. However, over the ensuing 4 days, the patient’s
clinical condition worsened with an incipient renal failure
and overlap of bradycardia. We performed an echocardio-
gram, which showed right ventricle failure with progressive
elevation of right-sided filling pressures (central venous
pressure, 35 mm Hg) and poor cardiac output. After the im-
plantation of a right-sided dual-chamber pacemaker, more
chronic RV support was required as a bridge to possible re-
transplantation, and an IVAD was inserted (Figure 1).
Over the next 53 days, there was clinical and echocardio-
graphic evidence of progressive improvement in RV func-
tion despite severe tricuspid regurgitation. Then, RVAD
explantation, combined with tricuspid valve ring annulo-
plasty, was successfully performed. Subsequent postopera-
tive recovery was uneventful with good RV function, and
the patient was discharged home 27 days later (Figure 2).FIGURE 1. Postoperative computed tomographic scan showing Thoratec
implantable right ventricular assist device in situ.
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FIGURE 2. Discharge chest radiograph showing dual lead pacer in place.
Pulmonary vasculature is normal. No edema, no pneumothorax. There are
residual tiny pleural effusions on the right side.
Brief Clinical ReportsAt 28 months’ follow-up, TTE and right heart catheteriza-
tion revealed normal left ventricular size and function, EF
60%; mild RV dilatation with mildly reduced RV systolic
function; moderate regurgitation of the mitral and tricuspid
valves, mean right atrial pressure of 4 mm Hg; and cardiac
index 4.1 L $min1 $m2.DISCUSSION
Registry data from the International Society of Heart and
Lung Transplantation shows that despite advances in peri-
operative management, RV dysfunction is still a cata-
strophic event after heart transplantation. Indeed, it
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mortality of 19%.4
Early deaths due toRVdysfunction after cardiac transplanta-
tion are attributable to either an increase in pulmonary vascular
resistance in the recipient or a loss of contractility in the donor
heart.5 In this patient, it is likely that the combination of chronic
pulmonary hypertension, moderate donor allograft left ventric-
ular hypertrophy, and long cold ischemic time of the donor al-
lograft contributed to perioperative RV dysfunction.
Chen and colleagues3 described their experience of tem-
porary RV support, and the maximum support period time
was 190 hours. The present case is unique in that the patient
was successfully weaned from the RVAD after 53 days of
support, and the recovered right ventricle is still functioning
well more than 2 years postoperatively. To the best of our
knowledge, this is the longest support to RV failure after
heart transplantation. This case suggests that the RV failure
following heart transplantation is reversible, and its recovery
is possible beyond 50 days. We should consider the long-
term use of the RVAD as an option in managing refractory
primary graft failure following heart transplantation.
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perforation in an infant: A case reportAtsushi Kawaguchi, MD, Kenji Waki, MD, Yoshio Arakaki, MD, and Kiyoshi Baba, MD, Shizuoka, JapanCongenital aneurysm of the sinus of Valsalva (ASV) is a rare
cardiovascular anomaly in infants. ASV usually affects only
one aortic sinus and is silent until rupture occurs. Only a few
cases of multiple ASV have been reported1-3 and cardiac
failure resulting from aortic regurgitation in an infant with
ruptured ASV is very uncommon. Here, we report the case
of a 5-month-old male infant with ruptured multiple ASV
and severe aortic regurgitation.ery c March 2010
